Display options
Cite
Coelho V, Faria AM. HSP60: issues and insights on its therapeutic use as an immunoregulatory agent. Front Immunol. 2012;2:97doi: 10.3389/fimmu.2011.00097.
Coelho, V., & Faria, A. M. (2011). HSP60: issues and insights on its therapeutic use as an immunoregulatory agent. Frontiers in immunology, 297. https://doi.org/10.3389/fimmu.2011.00097
Coelho, Verônica, and Faria, Ana M C. "HSP60: issues and insights on its therapeutic use as an immunoregulatory agent." Frontiers in immunology vol. 2 (2011): 97. doi: https://doi.org/10.3389/fimmu.2011.00097
Coelho V, Faria AM. HSP60: issues and insights on its therapeutic use as an immunoregulatory agent. Front Immunol. 2012 Jan 12;2:97. doi: 10.3389/fimmu.2011.00097. eCollection 2011. PMID: 22566886; PMCID: PMC3342027.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2012 Jan 12;2:97. doi: 10.3389/fimmu.2011.00097. eCollection 2011.

HSP60: issues and insights on its therapeutic use as an immunoregulatory agent.

Frontiers in immunology

Verônica Coelho, Ana M C Faria

Affiliations

  1. Laboratório de Imunologia, Instituto do Coração, Universidade de São Paulo São Paulo, Brazil.

PMID: 22566886 PMCID: PMC3342027 DOI: 10.3389/fimmu.2011.00097

Abstract

Heat shock proteins 60 (HSP60) is one of the most well studied member of the HSP family. Although found to be a target self antigen in pathological autoimmunity and HSP60-reactive T and B cells are part of immune responses in several infectious diseases, there is consistent experimental evidence that HSP60 displays dominant immunoregulatory properties. There are a series of reports on animal models showing that the administration of HSP60 can modulate inflammatory diseases. However, HSP60 has both immune-regulatory and inflammatory properties placing it as an essentially homeostatic antigen, but with potentially harmful effects as well. There have been a series of reports on the successful use of HSP60 and its peptides as immune-modulatory agent for several models of autoimmune diseases and in some clinical trials as well. We believe that the potential risks of HSP60 as a therapeutic agent can be controlled by addressing important factors determining its effects. These factors would be route of administration, appropriate peptides, time point of administration in the course of the disease, and possible association with other modulatory agents.

Keywords: HSP60; heat shock proteins; homeostasis; immunoregulation; inflammation

References

  1. Immunol Rev. 2005 Aug;206:232-59 - PubMed
  2. Hum Immunol. 2004 Feb;65(2):124-34 - PubMed
  3. J Immunol. 1989 Nov 1;143(9):2844-9 - PubMed
  4. J Am Coll Cardiol. 2002 Oct 2;40(7):1333-8 - PubMed
  5. J Exp Med. 1995 Mar 1;181(3):943-52 - PubMed
  6. Clin Exp Immunol. 2006 Jul;145(1):183-9 - PubMed
  7. J Clin Invest. 2007 Mar;117(3):712-8 - PubMed
  8. J Exp Med. 1991 Oct 1;174(4):791-8 - PubMed
  9. Mol Cell Biol. 1988 Jan;8(1):371-80 - PubMed
  10. Trends Immunol. 2002 Mar;23(3):130-5 - PubMed
  11. Cancer Gene Ther. 2009 Jul;16(7):598-608 - PubMed
  12. Int Immunol. 2000 Jul;12(7):1041-50 - PubMed
  13. Diabetes Metab Res Rev. 2007 May;23(4):292-8 - PubMed
  14. Arthritis Rheum. 2004 Oct;50(10):3221-31 - PubMed
  15. Ann N Y Acad Sci. 1996 Feb 13;778:194-201 - PubMed
  16. Am J Trop Med Hyg. 2011 Jul;85(1):70-3 - PubMed
  17. Ocul Immunol Inflamm. 1999 Jun;7(2):69-74 - PubMed
  18. Diabetes Metab Res Rev. 2007 May;23(4):269-75 - PubMed
  19. Carcinogenesis. 2009 Jun;30(6):1049-57 - PubMed
  20. Springer Semin Immunopathol. 1991;13(1):99-113 - PubMed
  21. Transpl Immunol. 1995 Jun;3(2):114-23 - PubMed
  22. Immunol Today. 1991 Apr;12(4):105-10 - PubMed
  23. Annu Rev Immunol. 2006;24:571-606 - PubMed
  24. Adv Intern Med. 1992;37:295-311 - PubMed
  25. Immunity. 2008 Aug 15;29(2):249-60 - PubMed
  26. J Immunol. 2004 May 15;172(10):6435-43 - PubMed
  27. Eur J Immunol. 1987 Mar;17(3):351-7 - PubMed
  28. Semin Liver Dis. 1991 Aug;11(3):183-6 - PubMed
  29. J Immunol. 2006 Jul 1;177(1):192-200 - PubMed
  30. Electrophoresis. 1999 Aug;20(11):2269-79 - PubMed
  31. Nat Rev Immunol. 2007 Jul;7(7):569-74 - PubMed
  32. Nat Immunol. 2007 Apr;8(4):351-8 - PubMed
  33. J Autoimmun. 1999 Mar;12(2):121-9 - PubMed
  34. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3284-9 - PubMed
  35. J Immunol. 2005 Sep 15;175(6):3594-602 - PubMed
  36. Mech Ageing Dev. 1998 May 1;102(1):67-80 - PubMed
  37. J Immunol. 1998 May 1;160(9):4628-34 - PubMed
  38. Clin Microbiol Rev. 1999 Jan;12(1):19-39 - PubMed
  39. Cell Stress Chaperones. 2010 Mar;15(2):123-41 - PubMed
  40. Nature. 1988 May 26;333(6171):330-4 - PubMed
  41. Nat Rev Immunol. 2005 Apr;5(4):318-30 - PubMed
  42. Clin Exp Immunol. 2006 Nov;146(2):312-22 - PubMed
  43. Genes Dev. 1988 Jul;2(7):874-82 - PubMed
  44. Cell. 2006 May 5;125(3):443-51 - PubMed
  45. J Clin Invest. 1997 Jul 15;100(2):459-63 - PubMed
  46. Lancet. 1993 Jan 30;341(8840):255-9 - PubMed
  47. Clin Immunol. 2012 Feb;142(2):117-26 - PubMed
  48. Semin Immunol. 2003 Jun;15(3):135-44 - PubMed
  49. Dev Immunol. 1996;4(4):299-315 - PubMed
  50. J Infect Dis. 2004 Dec 1;190(11):2020-30 - PubMed
  51. J Clin Invest. 2006 Jul;116(7):2022-32 - PubMed
  52. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3088-91 - PubMed
  53. Transplant Proc. 2004 May;36(4):833-5 - PubMed
  54. Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11348-53 - PubMed
  55. Eur J Immunol. 1991 Apr;21(4):1089-92 - PubMed
  56. J Immunol. 1999 Mar 15;162(6):3212-9 - PubMed
  57. Trends Biochem Sci. 2008 Feb;33(2):71-9 - PubMed
  58. Cell Biol Int. 1997 May;21(5):315-20 - PubMed
  59. Clin Exp Immunol. 1992 Nov;90(2):271-4 - PubMed
  60. Nat Med. 2008 Feb;14(2):162-9 - PubMed
  61. Vaccine. 2011 May 23;29(23):4043-50 - PubMed
  62. J Immunol. 2004 Dec 15;173(12):7259-68 - PubMed
  63. Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5159-63 - PubMed
  64. Clin Immunol Immunopathol. 1992 Aug;64(2):121-8 - PubMed
  65. Immunol Today. 1990 Apr;11(4):129-36 - PubMed
  66. Curr Top Microbiol Immunol. 2005;293:43-71 - PubMed
  67. J Immunol. 2002 Nov 15;169(10):6030-5 - PubMed
  68. J Autoimmun. 1996 Apr;9(2):159-66 - PubMed
  69. Cell Stress Chaperones. 2008 Summer;13(2):119-25 - PubMed
  70. Eur J Immunol. 1992 Jun;22(6):1667-9 - PubMed
  71. Scand J Immunol. 2007 Jul;66(1):62-70 - PubMed
  72. Science. 1989 Sep 8;245(4922):1112-5 - PubMed
  73. Diabetes. 1995 Sep;44(9):1132-8 - PubMed
  74. Cell Mol Life Sci. 2007 Mar;64(6):742-51 - PubMed
  75. Clin Gastroenterol Hepatol. 2006 Jun;4(6):754-9 - PubMed
  76. Trends Immunol. 2001 Jul;22(7):350-1 - PubMed
  77. J Biol Chem. 2001 Aug 17;276(33):31332-9 - PubMed
  78. Cancer Gene Ther. 2008 Oct;15(10):676-84 - PubMed
  79. Cancer Biol Ther. 2008 Jun;7(6):801-9 - PubMed
  80. Circ J. 2011;75(10):2445-52 - PubMed
  81. J Autoimmun. 2010 May;34(3):J220-5 - PubMed
  82. J Autoimmun. 2003 Mar;20(2):135-45 - PubMed
  83. Clin Dev Immunol. 2006 Jun-Dec;13(2-4):143-57 - PubMed
  84. Cell Stress Chaperones. 1999 Mar;4(1):29-35 - PubMed
  85. PLoS One. 2010 Mar 23;5(3):e9422 - PubMed
  86. Trends Immunol. 2011 Feb;32(2):89-95 - PubMed
  87. Science. 2002 Nov 15;298(5597):1395-401 - PubMed
  88. Scand J Immunol. 2008 Nov;68(5):516-25 - PubMed
  89. Clin Exp Immunol. 2006 Oct;146(1):66-75 - PubMed
  90. J Immunol. 1993 Jan 15;150(2):499-507 - PubMed
  91. Clin Exp Immunol. 2004 Jul;137(1):201-8 - PubMed
  92. Circulation. 2002 Sep 24;106(13):1708-15 - PubMed
  93. J Biol Chem. 2007 Oct 26;282(43):31289-301 - PubMed
  94. Med Mycol. 1998;36 Suppl 1:45-51 - PubMed
  95. J Cutan Pathol. 2004 Oct;31(9):586-94 - PubMed
  96. Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18889-94 - PubMed
  97. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14615-21 - PubMed
  98. Protein Expr Purif. 2011 Oct;79(2):165-75 - PubMed
  99. Lancet. 2001 Nov 24;358(9295):1749-53 - PubMed

Publication Types